Serodus ASA Stock

Stocks

17-01-02	Serodus : Primary endpoint reached by SER150 Phase 2a study in Diabetic Nephropathy.	PU
16-12-08	Serodus : Q&A delisting from Oslo Axess	PU
16-11-23	Serodus : Extraordinary general meeting held	PU
16-11-23	Serodus : Viggo Harboe Holding 2006 ApS announces results of voluntary offer	PU
16-11-02	Serodus : Viggo Harboe Holding 2006 Aps Launces voluntary offer for outstanding shares in Serodus ASA – Acceptance period starting 31 October 2016	PU

1 day

-5.56%

Manager	Title	Age	Since
Arnstein Gunnestad Endresen CEO	Chief Executive Officer	73	2022-12-31
Henrik Mordhorst DFI	Director of Finance/CFO	-	2019-09-30
Daniel Capion PRN	Corporate Officer/Principal	-	2020-12-31

Director	Title	Age	Since
Søren Elmann Ingerslev CHM	Chairman	-	2016-12-31
Terri Sebree BRD	Director/Board Member	68	2014-03-31
Viggo Gunnersen Harboe BRD	Director/Board Member	80	2021-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERODUS ASA	-5.56%	+7.94%	-	-	0
WUXI APPTEC CO., LTD.	-1.79%	-2.27%	+43.23%	+99.78%	67.98B
ARGENX SE	-2.06%	-0.18%	+39.67%	+85.24%	64.94B
INSMED INCORPORATED	-0.31%	+6.54%	-12.96%	+377.83%	27.58B
BIONTECH SE	+0.86%	+1.65%	-7.74%	-13.58%	26.06B
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.90%	+33.13%	+14.91%	25.74B
GENMAB A/S	-1.46%	+0.42%	+23.61%	-16.76%	20.09B
PHARMAESSENTIA CORPORATION	-2.96%	-15.21%	+216.20%	+375.70%	17.16B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-4.88%	-6.60%	+559.57%	14.92B
EXELIXIS, INC.	-0.20%	+8.37%	+55.78%	+165.57%	14.62B
Average	-1.80%	+0.26%	+42.70%	+183.14%	31.01B
Weighted average by Cap.	-1.52%	+0.18%	+38.37%	+142.06%

Employees

Sector